Neil Gallagher - Apr 10, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Apr 10, 2023
Transactions value $
$4,837,500
Form type
4
Date filed
4/12/2023, 04:02 PM
Next filing
Feb 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $4.84M +250K $19.35 250K Apr 10, 2023 Common Stock 250K $19.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty five percent (25%) of the total number of shares underlying the option shall vest on April 10, 2024, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.